Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan;57(1):57-69.
doi: 10.1007/s43441-022-00439-4. Epub 2022 Aug 18.

Pharmacometrics: The Already-Present Future of Precision Pharmacology

Lorena Cera Bandeira  1 , Leonardo Pinto  2 , Cláudia Martins Carneiro  2
Affiliations
Review

Pharmacometrics: The Already-Present Future of Precision Pharmacology

Lorena Cera Bandeira et al. Ther Innov Regul Sci. 2023 Jan.

Abstract

The use of mathematical modeling to represent, analyze, make predictions or providing information on data obtained in drug research and development has made pharmacometrics an area of great prominence and importance. The main purpose of pharmacometrics is to provide information relevant to the search for efficacy and safety improvements in pharmacotherapy. Regulatory agencies have adopted pharmacometrics analysis to justify their regulatory decisions, making those decisions more efficient. Demand for specialists trained in the field is therefore growing. In this review, we describe the meaning, history, and development of pharmacometrics, analyzing the challenges faced in the training of professionals. Examples of applications in current use, perspectives for the future, and the importance of pharmacometrics for the development and growth of precision pharmacology are also presented.

Keywords: Modeling; Pharmacology; Pharmacometrics; Pharmacoterapy; Simulation.

PubMed Disclaimer

References

    1. Barrett JS, Fossler MJ, Cadieu KD, et al. Pharmacometrics: a multidisciplinary field to facilitate critical thinking in drug development and translational research settings. J Clin Pharmacol. 2008;48(5):632–49. - DOI
    1. Chan PLS, Holford NHG. Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol. 2001;41:625–59. - DOI
    1. Gobburu JV, Lesko LJ. Quantitative disease, drug, and trial models. Ann Rev Pharmacol Toxicol. 2008;49:291–301. - DOI
    1. Eddy DM, Archimedes SL. A trial-validated model of diabetes. Diabetes Care. 2003;26:3093–101. - DOI
    1. Bangs A. Predictive biosimulation and virtual patients in pharmaceutical R and D. Stud Health Technol Inform. 2005;111:37–42.

Publication types

LinkOut - more resources